ANCA-associated (pauci-immune) vasculitis with renal involvement
ANCA vasculitis · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Small-vessel vasculitis (GPA, MPA, EGPA) causing pauci-immune necrotising crescentic glomerulonephritis, often with rapidly progressive AKI and pulmonary involvement. Requires urgent immunosuppression to preserve kidney function and treat life-threatening features.
Red flags
- Haemoptysis / diffuse alveolar haemorrhage
- Rapidly rising creatinine or oligo-anuria
- Mononeuritis multiplex or neurological involvement
- Severe sepsis on immunosuppression
- Scleritis, saddle-nose or subglottic stenosis (GPA)
- Coexisting anti-GBM positivity (double-positive)
Assessment
Differential diagnosis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Anti-GBM disease (can coexist)
- Lupus nephritis / immune-complex GN
- Infective endocarditis-related GN
Investigations
- ANCA (PR3 and MPO by ELISA)
- Urinalysis with microscopy for dysmorphic RBCs/casts and urine ACR/PCR
- U&E, creatinine trend and FBC/CRP
- Anti-GBM antibody, ANA/dsDNA, complement (to exclude mimics)
- Chest imaging (CXR/CT) for pulmonary haemorrhage/nodules
- Renal biopsy for crescentic pauci-immune GN
Management
- Recognise RPGN pattern: rising creatinine with haematuria, red cell casts and proteinuria — treat as emergency
- Send urgent ANCA, anti-GBM and complement; arrange renal biopsy without delaying treatment in severe disease
- Assess for organ/life-threatening features: pulmonary haemorrhage, severe/dialysis-requiring AKI, alveolar bleeding
- Start high-dose glucocorticoids immediately (IV methylprednisolone pulses then oral prednisolone taper)
- Induce remission with rituximab or cyclophosphamide alongside steroids
- Use plasma exchange for diffuse alveolar haemorrhage or severe renal failure (dialysis-dependent/rapidly rising creatinine), per MEPEX/PEXIVAS-guided selection
- Give PCP prophylaxis (co-trimoxazole) and gastroprotection; screen for infection/TB/hepatitis before immunosuppression
- Support failing kidneys: manage AKI complications, dialysis if indicated
- Transition to maintenance immunosuppression (rituximab or azathioprine) after remission
- Taper steroids using a reduced-dose regimen (PEXIVAS-style) to limit toxicity
- Monitor ANCA titres, renal function and for relapse
- Address long-term cardiovascular, bone and infection-prophylaxis needs
Drugs & doses
Methylprednisolone 500 mg IV daily for 3 days (pulse induction)
Prednisolone 1 mg/kg/day PO (max 60-80 mg) then reduced-dose PEXIVAS taper
Rituximab 375 mg/m2 IV weekly x4 OR 1 g IV on days 0 and 14
Cyclophosphamide IV 15 mg/kg (max 1.2 g) every 2-3 weeks (dose-reduced for age/renal function) OR 2 mg/kg/day PO
Co-trimoxazole 480-960 mg PO daily (PCP prophylaxis)
Azathioprine 2 mg/kg/day PO (maintenance alternative)
Disposition
Admit under nephrology/rheumatology; urgent discussion with specialist vasculitis service. ICU/respiratory support for alveolar haemorrhage. Renal replacement if indicated.
Complications & pitfalls
- Irreversible renal failure requiring dialysis
- Fatal pulmonary haemorrhage
- Immunosuppression-related infection (incl. PCP)
- Relapse
- Subglottic/tracheal stenosis (GPA)
- Treatment toxicity (cyclophosphamide, steroids)
Exam pearls
- RPGN is a nephrological emergency — do not wait for biopsy to start steroids in severe disease
- Always check anti-GBM: double-positive patients exist and need plasma exchange
- Rituximab is at least as effective as cyclophosphamide and preferred for relapsing/fertility concerns
- Reduced-dose steroid tapers (PEXIVAS) cut infection without losing efficacy
- Reserve plasma exchange for alveolar haemorrhage or severe/dialysis-requiring renal disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.